Isha Chaudhari

Dr. Isha Chaudhari


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2023 in Journal of Cornea and Ocular Surface
Verified
Journal Article
Open access
ICIsha Chaudhari
Isha Chaudhari
ALAnshika Luthra
Anshika Luthra
RSRishabh Sah
Rishabh Sah
MAManisha Acharya
Manisha Acharya
AGArpan Gandhi
Arpan Gandhi
Acanthamoeba keratitis (AK) generally displays a protracted course with significant morbidity. This is partly due to the fact that it is often misdiagnosed as viral or fungal keratitis. It is associated most with contact lens (CL) wear in developed countries, and exposure to soil or unsanitary water in the developing countries. The textbook description of AK includes the presence of ring infiltration, radial keratoneuritis, and disproportionate pain. Of the patients that presented to our tertiary care center, only 40% had a history of CL use, and 33% had a ring infiltrate. Corneal scraping for microbiological culture on non-nutrient agar serves as the gold standard for diagnosis. Corneal biopsy and confocal microscopy hold diagnostic value in deeper lesions, and polymerase chain reaction and newer molecular techniques are emerging as rapid and effective tools. Biguanides are the drug of choice for AK. But it is important to reconstitute these drugs in correct dosages; otherwise, corneal toxicity can take place. The use of corticosteroids in AK is a matter of debate. We have used corticosteroids in cases with persistent keratitis, severe pain, and extra-corneal manifestations under the cover of amoebicidal therapy. Surgical intervention in the acute phase is reserved for advanced AK with limbus encroachment, perforations, or fulminant corneal abscesses. AK is thus a severe, potentially blinding disease, where a prompt diagnosis ensuring the timely commencement of amoebicidal therapy is an essential component of improving the patient’s prognosis. In this article, we have discussed the presentation, challenges in diagnosis and management, and our experience in managing AK.

1 October 2024 in Delhi Journal of Ophthalmology
Verified
Journal Article
Open access
ICIsha Chaudhari
Isha Chaudhari
NKNeha Kapur
Neha Kapur
Intraocular lens opacification (IOL) is an uncommon but known entity. As the opacification involves the substance of the IOL and not the posterior capsule, as seen in posterior capsular opacification, neodymium:yttrium–aluminum–garnet (Nd:YAG) laser treatment is ineffective. Furthermore, an attempt at a Nd:YAG laser treatment in a misdiagnosed opacified IOL, compromises the posterior capsule and jeopardizes IOL exchange, the only known treatment so far. The most commonly described cause of IOL opacification is surgical techniques involving air or gas injection. We describe three cases of IOL opacification without any history of a surgical procedure involving air or gas injection.

26 October 2026 in Cells
Verified
Journal Article
Open access
PDF file
Hon Shing OngHon Shing Ong
Hon Shing Ong
DMDeepika Malhotra
Deepika Malhotra
DNDawn Jing Hui Neo
Dawn Jing Hui Neo
XNXiao Yu Ng
Xiao Yu Ng
ICIsha Chaudhari
Isha Chaudhari
Jodhbir S. MehtaJodhbir S. Mehta
Jodhbir S. Mehta
Purpose: This study seeks to evaluate the effects of pre-treating donor corneal tissue with a Rho-associated kinase inhibitor (ROCKi), Netarsudil (AR-13324), on the viability of corneal endothelial cells (CECs) during Descemet’s membrane endothelial keratoplasty (DMEK) graft preparation and insertion using endothelium-in and endothelium-out techniques. Methods: This ex vivo comparative study utilized 24 pairs of research-grade human donor corneas preserved in Optisol-GS. One cornea from each pair was incubated in 1 µM AR-13324 for 2 h, while the contralateral cornea served as a control. DMEK tissues were prepared and simulated insertion was performed using either the endothelium-in (Endoglide) or endothelium-out (Geuder glass injector) technique. The surgeon performing the tissue preparation and insertion was masked to the ROCKi treatment allocation. Post-manipulation, tissues underwent live/dead cytotoxicity assay using Calcein-AM and Ethidium homodimer-1 staining. Percentages of live, fallout, and dead CECs were quantified via fluorescence microscopy and ImageJ (version 1.54p) analysis. Correlations between donor age, preservation duration, and cell viability were also analyzed. Results: For the endothelium-out model, live cell percentage was lower in controls compared to ROCKi-treated corneas (89.6 ± 5.35% vs. 95.1 ± 3.74%, p = 0.0001), while the percentage of dead cells was higher in controls (7.13 ± 3.71% vs. 2.16 ± 1.39%, p = 0.0017). For the endothelium-in model, live cell percentage was lower in controls compared to ROCKi-treated corneas (86.8 ± 4.81% vs. 94.4 ± 3.26%, p = 0.0001), with corresponding higher percentage fallout (8.21 ± 5.02% vs. 4.05 ± 2.82%; p = 0.0036) and higher percentage dead cells (5.04 ± 3.52% to 1.56 ± 1.13%; p = 0.0070). No significant correlations were found between donor age or preservation time and cell viability outcomes. Comparative analysis showed no significant difference in cell survivability between the two DMEK techniques with ROCKi treatment. Conclusions: Pre-incubation with the ROCKi AR-13324 significantly enhances corneal endothelial cell viability and reduces cell death during DMEK graft preparation and manipulation, regardless of the graft insertion technique used. Incorporating ROCKi treatment into tissue preparation protocols may enhance endothelial preservation, potentially expanding its clinical utility in eye banking and improving corneal graft survival.